disease 924 words KG: ent-dise-a2eb078f
Contents

Japan Neurodegeneration Epidemiology

Disease Info
OkinawaHighest longevity, highest dementia prevalence
Northern regions (Hokkaido, Tohoku)Higher rates
Urban areas (Tokyo, Osaka)Better diagnosis, higher reported rates
DatabasesOMIMOrphanetClinicalTrialsPubMed

No AI portrait yet

Knowledge Graph

Agent Input

💡 Improve this page

🌐 Cross-references

OMIMMeSHWikipedia

Related Hypotheses (181)

Lysosomal Calcium Channel Modulation Therapy
Score: 0.70
Perforant Path Presynaptic Terminal Protection Strategy
Score: 0.70
Axonal RNA Transport Reconstitution
Score: 0.70
Mitochondrial Transfer Pathway Enhancement
Score: 0.70
Complement C1q Mimetic Decoy Therapy
Score: 0.69
Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th
Score: 0.69
Palmitoylation-Targeted BACE1 Trafficking Disruptors
Score: 0.69
Ocular Immune Privilege Extension
Score: 0.69
Sphingomyelin Synthase Activators for Raft Remodeling
Score: 0.69
Extracellular Matrix Stiffness Modulation
Score: 0.69
Ganglioside Rebalancing Therapy
Score: 0.69
Reelin-Mediated Cytoskeletal Stabilization Protocol
Score: 0.69
Cross-Seeding Prevention Strategy
Score: 0.69
Hypocretin-Neurogenesis Coupling Therapy
Score: 0.69
Lysosomal Positioning Dynamics Modulation
Score: 0.69
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.69
Pericyte Contractility Reset via Selective PDGFR-β Agonism
Score: 0.68
Flotillin-1 Stabilization Compounds
Score: 0.68
R-Loop Resolution Enhancement Therapy
Score: 0.68
Chaperone-Mediated APOE4 Refolding Enhancement
Score: 0.68
← Prevpg 4/10Next →

Related Analyses (30)

SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
Astrocyte Reactivity Subtypes in Neurodegeneration
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed

Related Experiments (30)

Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40

See Also (15)

Metabolomic Biomarkers in Neurodegeneration
biomarker · Pages share 139 hypotheses
Adrenal Chromaffin Cells in Neurodegeneration
cell · Pages share 139 hypotheses
MDS 2026 — Fluid Biomarker Advances in Neurodegeneratio
event · Pages share 139 hypotheses
Blood-Based Biomarkers for Neurodegeneration
biomarker · Pages share 139 hypotheses
Neuroimaging Biomarkers for Neurodegeneration
biomarker · Pages share 139 hypotheses

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

💬 Discussion (Talk page)

Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.